我国狂犬病疫苗市场仍存在较大增长潜力,狂犬病疫苗的技术迭代升级正在加速,包括艾美疫苗、CureVac在内的多家企业和科研机构,已经开发了新型mRNA狂犬病疫苗。日前,中国药科大研究团队在期刊Molecular Therapy上发表研究论文指出,mRNA疫苗能够以较低剂量即在恒河猴体内诱导高水平的病毒中和抗体(VNA)、持续的体液和细胞反应以及免疫记忆,并具有良好的安全性,在小鼠中可对致命的狂犬病毒...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.